Abstract
Objective: To evaluate the therapeutic effects of paliperidone and risperidone orally disintegrating tablets on schizophrenia (SCH). Methods: A total of 66 hospitalized SCH patients admitted between April 2022 and October 2023 were selected. They were randomly divided into two groups using a random number table. The study group was treated with paliperidone, while the control group was treated with risperidone orally disintegrating tablets. Differences in efficacy, symptom scores, and adverse reaction rates were compared between the two groups. Results: The overall efficacy rate in the study group was similar to that of the control group (P > 0.05). After three months of treatment, Positive and Negative Syndrome Scale scores in both groups were significantly lower than those before treatment, with the study group exhibiting lower symptom scores than the control group (P < 0.05). The adverse reaction rate in the study group was lower than that in the control group (P < 0.05). Conclusion: Paliperidone demonstrates therapeutic efficacy for SCH patients comparable to risperidone orally disintegrating tablets. However, paliperidone significantly improves disease symptoms and reduces medication-related side effects.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call